Edwin M. Posadas, MD, FACP
Edwin M. Posadas, MD, FACP is Medical Director of the Urologic Oncology Program at Cedars-Sinai’s Samuel Oschin Comprehensive Cancer Institute.
Dr. Posadas has both clinical and research interests in the treatment of advanced prostate cancer and the biology of cancer metastasis. Dr. Posadas is studying the mechanisms through which cancer cells in localized tumors spread to other parts of the body. A protein called FYN, a member of a cancer-causing gene family, was identified in his laboratory as a possible regulator of metastasis. At Cedars-Sinai, Dr. Posadas will work to comprehensively define the function of FYN in prostate cancer cells, with the goal of applying his basic science findings to the development of new therapies that will directly benefit men with advanced prostate cancer. He joins Dr. Leland Chung, director of the Samuel Oschin Comprehensive Cancer Institute’s Uro-Oncology Research Program and a full team of researchers and physicians committed to advancing progress in the diagnosis and treatment of genitourinary cancers.
Dr. Posadas joined Cedars-Sinai from the University of Chicago, where he was an assistant professor of medicine and surgery. While at Chicago, he received the Prostate Cancer Foundation’s Stewart Rahr-PCF Young Investigator Award. Prior to that appointment, Dr. Posadas served as an assistant clinical investigator at the National Cancer Institute. He earned his undergraduate and medical degrees at Johns Hopkins University and served his residency at the University of Michigan Medical Center.
Dr. Posadas is a frequent reviewer for the journals Cancer and Cancer Research, among others. His research has been published in major peer-reviewed journals, including the Journal of Clinical Oncology and Clinical Cancer Research.